• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form S-3/A filed by DarioHealth Corp.

    12/29/25 4:05:31 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care
    Get the next $DRIO alert in real time by email
    S-3/A 1 tm2534209d1_s3a.htm FORM S-3/A

     

    As filed with the Securities and Exchange Commission on December 29, 2025

     

    Registration No. 333-290969 

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    AMENDMENT NO. 1 TO

    FORM S-3/A

    REGISTRATION STATEMENT

    UNDER THE SECURITIES ACT OF 1933

     

    DARIOHEALTH CORP.

    (Exact Name of Registrant as Specified in Its Charter)

     

    Delaware
    (State or other jurisdiction
    of incorporation or organization)
    45-2973162
    (I.R.S. Employer
    Identification No.)

     

    322 W. 57th St. #33B

    New York, New York 10019

    Telephone: (972) 4-770-6377

    (Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

     

    Mr. Erez Raphael

    Chief Executive Officer

    DarioHealth Corp.

    322 W. 57th St. #33B

    New York, New York 10019 

    Telephone: (972) 4-770-6377

    (Name, address, including zip code, and telephone number,

    including area code, of agent for service)

     

    Copies to:

    Oded Har-Even, Esq.

    Ron Ben-Bassat, Esq.

    Sullivan & Worcester LLP

    1251 Avenue of the Americas

    New York, New York 10020

    Telephone: (212) 660-5000

    Facsimile: (212) 660-3001

     

    Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this registration statement, as determined by market and other conditions.

     

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ¨

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: x

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

     

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ¨

     

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ¨

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer: ¨ Accelerated filer: ¨
    Non-accelerated filer: x Smaller reporting company: x
      Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ¨

     

    THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE COMMISSION ACTING PURSUANT TO SAID SECTION 8(a), MAY DETERMINE.

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Pre-Effective Amendment No.1 (the “Amendment”) is being filed to amend the Registration Statement on Form S-3 (File No. 333-290969), originally filed by the registrant on October 20, 2025 (the “Registration Statement”). The sole purpose of this Amendment is to file an updated Exhibit 23.1 and in connection therewith to amend and restate the exhibit index set forth in Part II of the Registration Statemen. Accordingly, this Amendment consists only of the cover page of the Registration Statement, this Explanatory Note, the Exhibit Index to the Registration Statement, the signature pages and Exhibit 23.1 filed herewith. This Amendment does not modify any provision of the prospectus contained in Part I or the balance of Part II of the Registration Statement.

     

    Item 16. Exhibits

     

    EXHIBIT INDEX

     

    Exhibit
    No.
      Description
    4.1^   Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on September 25, 2025)
    5.1^   Opinion of Sullivan & Worcester LLP
    10.1^   Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 the Current Report on Form 8-K filed with the Securities and Exchange Commission on September 25, 2025)
    23.1*   Consent of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global
    23.2*   Consent of Sullivan & Worcester LLP (included in Exhibit 5.1)
    24.1^   Power of Attorney
    107^   Filing Fee Table

     

    * Filed herewith

    ^ Previously filed

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Caesarea, Israel on the 29th day of December 2025.

     

      DARIOHEALTH CORP.
         
      By: /s/ Erez Raphael
      Name: Erez Raphael
      Title: Chief Executive Officer

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the dates indicated.

     

    Person   Capacity   Date
             
    /s/ Erez Raphael   Chief Executive Officer   December 29, 2025
    Erez Raphael   (Principal Executive Officer)    
             
    /s/ Chen Franco-Yehuda   Chief Financial Officer, Secretary and Treasurer   December 29, 2025
    Chen Franco-Yehuda   (Principal Financial and Accounting Officer)    
             
    *   Chairman of the Board of Directors   December 29, 2025
    Yoav Shaked        
             
    *   Director   December 29, 2025
    Lawrence Leisure        
             
    *   Director   December 29, 2025
    Hila Karah        
             
    *   Director   December 29, 2025
    Dennis Matheis        
             
    *   Director   December 29, 2025
    Dennis M. McGrath        
             
    *   Director   December 29, 2025
    Adam Stern        

     

    * /s/ Erez Raphael        
    Erez Raphael        
    Attorney-in-fact        

     

     

     

     

    Get the next $DRIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DRIO

    DatePrice TargetRatingAnalyst
    1/29/2025$2.00 → $1.00Buy → Hold
    TD Cowen
    5/13/2022$8.75Neutral → Buy
    Alliance Global Partners
    1/26/2022$28.00 → $25.00Buy
    Aegis Capital
    8/19/2021$35.00 → $28.00Buy
    Aegis Capital
    More analyst ratings

    $DRIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CCO Nelson Steven Charles was granted 30,000 shares, increasing direct ownership by 632% to 34,750 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    9/15/25 6:04:08 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Director Stern Adam K was granted 20,000 shares, increasing direct ownership by 206% to 29,717 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    9/15/25 6:03:10 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Director Leisure Lawrence B. was granted 20,000 shares (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    9/15/25 4:20:39 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CCO Nelson Steven Charles bought $21,200 worth of shares (40,000 units at $0.53), increasing direct ownership by 73% to 95,000 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    8/27/25 4:30:59 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Nelson Steven Charles bought $4,546 worth of shares (5,000 units at $0.91), increasing direct ownership by 10% to 55,000 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    11/14/24 4:15:15 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Nelson Steven Charles bought $8,244 worth of shares (10,000 units at $0.82), increasing direct ownership by 25% to 50,000 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    9/12/24 4:37:42 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $DRIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $DRIO
    SEC Filings

    View All

    Dario Launches DarioIQ™ AI Integration in Dario Health App with Direct-to-Consumer First Version for Hypertension Members

    First in-market activation of Dario's GenAI roadmap lays clinical and technical foundation for a seamless, conversational AI experience across the entire Dario platform DarioIQ™ reflects years of innovation in data science, engineering and clinical design backed by Dario's proprietary AI models and 13 billion real-world data points, further reinforcing Dario's position as a leader in digital health NEW YORK, Dec. 10, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced the launch of the Dario Health app enhanced with DarioIQ™, the Company's new artificial intelligence ("AI") layer, delivered as a di

    12/10/25 8:00:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Dario's Data-Driven Digital Health Platform Delivers Significant and Sustainable Improvements in Blood Pressure: Findings Published in JMIR Cardio

    Peer-reviewed JMIR Cardio study demonstrates real-world clinical impact of data-driven digital nudges on hypertension outcomes Data-driven engagement translates to lower health risks and downstream cost savings for Dario clients Results highlight Dario's ability to deliver lasting impact and further cement the Company's position as a proven leader in evidence-based digital care    NEW YORK, Dec. 4, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced publication of a new peer-reviewed study in JMIR Cardio demonstrating that data-driven nudges delivered via Dario's digital health platform are associa

    12/4/25 8:00:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth Far Exceeds 2025 New Client Target with 79 New Accounts Signed Year-to-Date

    34 new employer clients added in the past two weeks expected to contribute to H1 2026 revenue Data-driven outcomes drive employer adoption, highlighting Dario's market leadership as partner of choice, underscoring employer confidence, repeatability and scalability NEW YORK, Dec. 2, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced that it has secured 34 new employer clients in the past two weeks, reaching a total of 79 clients signed year-to-date, exceeding its 2025 target of 40 new clients by 98%. These new agreements, which collectively represent tens of thousands of covered lives, further vali

    12/2/25 8:00:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth downgraded by TD Cowen with a new price target

    TD Cowen downgraded DarioHealth from Buy to Hold and set a new price target of $1.00 from $2.00 previously

    1/29/25 7:36:04 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth upgraded by Alliance Global Partners with a new price target

    Alliance Global Partners upgraded DarioHealth from Neutral to Buy and set a new price target of $8.75

    5/13/22 9:01:42 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Aegis Capital reiterated coverage on DarioHealth with a new price target

    Aegis Capital reiterated coverage of DarioHealth with a rating of Buy and set a new price target of $25.00 from $28.00 previously

    1/26/22 10:35:44 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by DarioHealth Corp.

    EFFECT - DarioHealth Corp. (0001533998) (Filer)

    1/9/26 12:15:07 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form S-3/A filed by DarioHealth Corp.

    S-3/A - DarioHealth Corp. (0001533998) (Filer)

    12/29/25 4:05:31 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    SEC Form DEF 14A filed by DarioHealth Corp.

    DEF 14A - DarioHealth Corp. (0001533998) (Filer)

    12/22/25 4:12:29 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Leadership Updates

    Live Leadership Updates

    View All

    DarioHealth Appoints Healthcare Industry Leader Larry Leisure to Board of Directors

    Healthcare innovator and former Accenture executive brings deep industry relationships to advance Dario's AI-driven chronic care platform. NEW YORK, Feb. 27, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in AI-driven digital health solutions, today announced the appointment of Lawrence (Larry) B. Leisure to its Board of Directors, bringing four decades of healthcare leadership, managed care expertise, and digital health innovation to the company's governance. Mr. Leisure's extensive experience working with health plans, health systems, consultants, and employer coalitions, combined with his deep understanding of health policy, reimbursement, and va

    2/27/25 8:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

    Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced the appointments of Avril McKean Dieser, MA, JD and Olivier R. Jarry, MS, MBA as independent members of the Company's Board of Directors. Collectively, Ms. McKean Dieser and Mr. Jarry bring over 50 years of biopharmaceutical executive decision-making experience to the Company, with a specific focus in commercializing biologic products. "OS Therapies is thrilled to welcome Ms. McKean Dieser and Mr. Jarry to our Board of Directors," sa

    10/28/24 4:44:00 PM ET
    $BMY
    $DRIO
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Empowering Commercial Expansion: DarioHealth Announces Strategic Reorganization and Appoints Inaugural Chief Commercial Officer

    After two decades of successfully scaling multiple healthcare companies, Steven Nelson joins DarioHealth as Chief Commercial Officer to accelerate revenue growth across the health plans, employers and pharma channels NEW YORK, June 5, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario", "DarioHealth" or the "Company"), a leader in the global digital health market, announced today a strategic reorganization designed to streamline leadership and focus the organization on accelerating its commercialization efforts. This move reflects the Company's commitment to bringing its innovative solutions to the market faster, maximizing customer impact, and driving the organization to profitabi

    6/5/24 8:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Financials

    Live finance-specific insights

    View All

    DarioHealth Reports Third Quarter 2025 Financial and Operating Results

    Third quarter 2025 revenue was $5.0 million, compared to $7.4 million in the third quarter of 2024, and $5.4 million in the second quarter of 2025 Targeting $12.4 million in new business, reflecting both committed annual recurring revenue ("CARR") and late-stage opportunities nearing completion; 2026 pipeline expanded to $69 millionExceeded 2025 goal of 40 new signed accounts for 2026 revenue, with 45 new signed accounts to date—several already contributing to 2025 results; average employer customer size nearly doubled what was projectedStrong business fundamentals in the third quarter including GAAP gross margin increase to 60%, 7 consecutive quarters of 80%+ non-GAAP gross margins on core

    11/13/25 6:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth to Report Third Quarter 2025 Results on Thursday, November 13, 2025

    Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, Nov. 6, 2025 /PRNewswire/ --DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 3rd quarter ended September 30th, 2025 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Thursday, November 13th, 2025, before the market opens. Erez Raphael, Chief Executive Officer, Steven Nelson, President and Chief Commercial Officer, and Chen Franco-Yehuda, Chief Financial Officer, will host the call. Conference Call Details Date: Thursday, November 13th, 2025, 8:30 a.m. Eastern Time Di

    11/6/25 8:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth Announces 20-to-1 Reverse Stock Split

    NEW YORK, Aug. 25, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced that a reverse stock split of the Company's issued and outstanding common stock, par value $0.0001 per share (the "Common Stock") at a ratio of 20-for-1 is expected to be implemented at market open on August 28, 2025. The Company's Common Stock will begin trading on the Nasdaq Capital Market on a post-split basis at the market open on August 28, 2025, under the Company's existing trading symbol "DRIO", but will trade under a new CUSIP Number, 23725P 308. After giving effect to the reverse share split of the Company's Common Stock,

    8/25/25 8:00:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by DarioHealth Corp.

    SC 13G - DarioHealth Corp. (0001533998) (Subject)

    12/13/24 4:05:12 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by DarioHealth Corp.

    SC 13G - DarioHealth Corp. (0001533998) (Subject)

    10/29/24 11:45:28 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by DarioHealth Corp. (Amendment)

    SC 13G/A - DarioHealth Corp. (0001533998) (Subject)

    2/14/24 4:51:40 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care